Publications & Posters Featuring Our Proprietary Oncology Data

Sharing our research with the field and helping to shape the discussion of best practices in the treatment of patients with cancer is a key area of focus for Xcenda. This is evidenced by publications in peer-reviewed journals and poster presentations at major scientific congresses.  The products and market research consulting services of NMCR Analytics are now part of the newly expanded market research practice at Xcenda.  Highlights of our work includes:

Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): a pooled molecular reanalysis of randomized chemotherapy trials.
Abstract #476 from the 2010 ASCO Gastrointestinal Cancers Symposium

Management of N3 stage IIIB NSCLC: Changes in U.S. physician behavior following ASCO 2007.
Abstract: #7579 from the 2008 ASCO Annual Meeting

Patterns of planned post-operative management among U.S. medical oncologists (USMO) after neo-adjuvant chemoradiotherapy (nCRT) and surgery for stage III rectal cancer (RC).
Abstract: #6602 from the 2008 ASCO Annual Meeting

Impact of 2006 ASCO Annual Meeting data release of Cancer and Leukemia Group B (CALGB) protocol 9633 on practice patterns in the United States.
Abstract: #7547 from the 2008 ASCO Annual Meeting

Three-year analysis of the use of erlotinib combined with gemcitabine as first-line therapy in patients with advanced pancreatic cancer.
Abstract: #209 from the 2008 ASCO Gastrointestinal Cancers Congress

Journal of Thoracic Oncology
Irinotecan-cisplatin Ttherapy for Patients with Extensive Stage Small Cell Llung Cancer: Use Patterns Among American Medical Oncologists 2000-2006. Journal of Thoracic Oncology. 2007(10):953-6. 

The Oncologist
How Do U.S. Medical Oncologists Learn and Apply New Clinical Trials Information From Press Releases on the Non-medical Media? A Case Study Based on ECOG 4599. The Oncologist. 2006(11);1:31-8.

Journal of Oncology Practice
Adjuvant Ttherapy Choices In Patients with Resected Non-small Cell Lung Cancer: Correlation of Doctors’ Treatment Plans and Relevant Phase III Trial Data. Journal of Oncology Practice. 2005(1);2: 37-42.